



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

January 9, 2026

To

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sir / Madam,

Sub.: Clarification on XBRL submission of Unaudited Financial Results for the quarter and half year ended September 30, 2025.

This is reference to the captioned subject, and your email dated January 7, 2026.

Please note that the Board of Directors of the Company at its meeting held on November 12, 2025, approved the unaudited financial results for the quarter and half year ended September 30, 2025. The Company had accordingly filed the applicable submissions in PDF mode as well as XBRL mode with the Stock Exchanges within the prescribed timelines.

It may be noted that while submitting the Unaudited financial results for the quarter and half year ended September 30, 2025, the 'Reporting Type' was selected as 'Quarterly' and the 'Reporting Quarter' was selected as 'Half Year'. The Company thereafter received an email dated November 28, 2025, from the National Stock Exchange of India Limited advising us to submit the revised Integrated Filing - Financials by selecting Reporting Type as 'Quarterly' and Reporting Quarter as 'Second quarter'.

Accordingly, the Company filed the Integrated Filing - Financials XBRL with the required changes on November 28, 2025. Enclosed are the snapshot and the acknowledgement of the same for your reference. It may be noted that the revised Integrated Filing submitted on November 28, 2025, which reflects on NSE's website, captures details of quarterly financial results and half yearly financial results for the period ended September 30, 2025.

Trust the above clarifies.

Yours truly,

For **Pfizer Limited**

Prajeet Nair

Director- Corporate Services & Company Secretary

CIN: [L24231MH1950PLC008311](#)

Email ID: contactus.india@pfizer.com

Website: www.pfizerltd.co.in



National Stock Exchange Of India Limited

Date of

09-Jan-2026

NSE Acknowledgement

Symbol :-	PFIZER
Name of the Company :-	Pfizer Limited
Module :-	Integrated Filing- Non-Banking Ind AS
Submission Type :-	Revision
Quarter/Period Ended :-	30-Sep-2025
Date of Submission :-	28-Nov-2025 17:33:59
NEAPS App. No :-	129724

Disclaimer :We acknowledge the receipt of your submission through NEAPS. The information provided by you has been disseminated on the website on as is basis.

NSE NSE's Electronic Application Processing System (NEAPS) Pfizer Limited Discla Welcome Prajeet 28-Nov-2025 05:34:05 PM

HOME MASTER ISSUE COMPLIANCE PAYMENT REPORT HELP VALUE ADDED SERVICES FINANCIAL REVIEW Customize Menu

NEAPS > COMPLIANCE > Common XBRL Upload

Common XBRL Upload

30-Sep-2025

Board Meeting Start Time 14 : 00 (24Hr Format) Board Meeting End time 15 : 15 (24Hr Format)

Result Type Non-Banking Ind AS Consolidated / Standalone Standalone

Attachment PDF Type Of Submission Revision

Application No. of previous submission 126521

Financial Year To 31-Mar-2026

Reason for Non-Submission of Consolidated Financial Results Company does not have subsidiaries

XBRL Upload

Upload XBRL

Select File

Upload Close

File uploaded Successfully

as S

Upload XBRL File

Note:
1. It is advised that latest Excel Utility should be used every time for XBRL filing.
2. Click on respective Excel Utility hyperlink to download. Please refer the detailed instructions available in the utility.

Download Offline Excel Utilities
Copyright © 2020 National Stock Exchange of India Ltd. All rights reserved. Best viewed in Chrome and 1366 X 768 resolution.

Please note that the contact details of the entities and its Officials, registered on the NEAPS portal, may be used by the Exchange to send various communication viz. Regulatory updates, Acknowledgements, Approvals etc., from time to time, either individually or on bulk-basis

Sunset 5:59 pm Search ENG IN 05:34 PM 28-11-2025